In vitro evaluation revealed aztreonam-nacubactam significantly lowered MICs in Stenotrophomonas maltophilia, indicating its potential against resistant infections.
We evaluated the in vitro activity of aztreonam-nacubactam (ATM-NAC) and cefepime-nacubactam (FEP-NAC) against 53 clinical isolates of Stenotrophomonas maltophilia from blood cultures. Minimum inhibitory concentrations (MICs) were determined via broth microdilution. While ATM-NAC showed more significant MIC reduction, FEP-NAC also remarkably decreased MICs, despite cefepime being a substrate for L1 β-lactamase. These findings suggest the potential of β-lactam–NAC combinations as promising alternatives, warranting further in vivo studies to confirm clinical applicability.
No takes yet. Share an insight, caveat, or question.
Aoki et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: